NCT00085358 - Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2011

Conditions

Brenner TumorFallopian Tube CancerOvarian CarcinosarcomaOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaPrimary Peritoneal Cavity CancerStage II Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer

Interventions

DRUG

carboplatin

Given intraperitoneally

DRUG

paclitaxel

Given IV or intraperitoneally

DRUG

docetaxel

Given IV

BIOLOGICAL

bevacizumab

Given IV

Trial Locations (16)

19103

Gynecologic Oncology Group, Philadelphia

21204

Greater Baltimore Medical Center, Baltimore

44060

Lake University Ireland Cancer Center, Mentor

44106

Case Western Reserve University, Cleveland

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

52242

University of Iowa Hospitals and Clinics, Iowa City

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

74104

Cancer Care Associates-Midtown, Tulsa

80010

Colorado Gynecologic Oncology Group, Aurora

92868

University of California Medical Center At Irvine-Orange Campus, Orange

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

21287-8936

Johns Hopkins University, Baltimore

08103

Cooper Hospital University Medical Center, Camden

74136-1929

Cancer Care Associates-Yale, Tulsa

02905

Women and Infants Hospital, Providence

All Listed Sponsors

collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH